Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | KCNN4 | O15554 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 2/20 | 0.38 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PDE6D | O43924 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6403766 | 0.78 | GAA (0.44) | GAATSHRALDH1A1TNKS2KDM1A | |
| SCHEMBL6399674 | 0.78 | LMNA (0.50) | TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL6401309 | 0.78 | LMNA (0.50) | TSHRALDH1A1MEN1KMT2A | |
| SCHEMBL6398623 | 0.70 | ESR1 (0.40) | ALDH1A1HSD17B10MEN1KMT2AKDM4E | |
| SCHEMBL6137239 | 0.68 | ALDH1A1 (0.43) | GAATSHRALDH1A1CYP2C19HSD17B10 | |
| SCHEMBL6404733 | 0.66 | ALDH1A1 (0.47) | GAAALDH1A1CYP2C19KDM4E | |
| SCHEMBL669693 | 0.65 | HTR2C (0.50) | GAA | |
| SCHEMBL6399098 | 0.65 | HDAC1 (0.49) | GAAALDH1A1POLBCYP2C19KMT2A | |
| SCHEMBL30023288 | 0.64 | GAA (0.57) | GAAALDH1A1TNKS2KDM1AKDM1B | |
| SCHEMBL11652329 | 0.64 | GAA (0.57) | GAAALDH1A1TNKS2KDM1AKDM1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050054696-A1 | Indole compounds and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-10 | — | — | US | claimed |
| EP-1452526-A1 | INDOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | claimed |
| US-20050054696-A1 | Indole compounds and medicinal use thereof | JAPAN TOBACCO INC. (JP) | 2005-03-10 | — | — | US | disclosed |
| EP-1452526-A1 | INDOLE COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054696-A1 | Indole compounds and medicinal use thereof | IDO1, GPR119, SLC5A1 | GAA 1100/4885TSHR 1304/4885KCNN4 1273/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.